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Hepatic resection is the mainstay of curative
treatment for hepatocellular carcinoma (HCC), with
perioperative and survival results improving in recent
years.
1 Radiofrequency ablation (RFA) is a rapidly
growing thermal ablative therapy for small HCC that
is also potentially curative. Prospective randomized
trials have shown that RFA is superior to ethanol
injection in inducing complete tumor necrosis,
resulting in better long-term progression-free and
overall survival.
2,3 Furthermore, a recent randomized
trial suggested that RFA might achieve similar long-
term survival results compared with resection for
solitary HCC <5 cm in diameter, although more
data from further randomized trials are needed to
provide better evidence.
4 Although RFA is competi-
tive with resection in the treatment of a small solitary
HCC, RFA and resection could be complementary to
each other in the management of multifocal HCCs.
Combined hepatectomy and radiofrequency ablation
for multifocal hepatocellular carcinomas: long-term
follow-up results and prognostic factors Choi et al.
5
reported favorable perioperative results and long-
term survival in a series of 53 patients who had
undergone combined resection and ablation for
multifocal HCCs. This study demonstrated an
important role for RFA in increasing the chance of
curative treatments for patients with multifocal tu-
mors that may otherwise be considered unresectable.
The role of combined resection and ablation has
been previously reported in patients with colorectal
liver metastasis.
6 Combined resection and RFA may
play an even more important role in the management
of HCC because of the high frequency of multifocal
tumors and associated cirrhosis, which limits the
applicability of extended resection to encompass
multifocal or bilobar HCCs. A previous study of
patients with bilobar HCCs diagnosed after laparos-
copy or laparotomy has shown that combined
resection of HCC in one lobe and wedge resection or
ethanol ablation of lesions in the contralateral lobe
greatly prolonged the long-term survival compared
with nonsurgical treatments.
7 However, wedge
resection for contralateral lobe lesions can only be
performed for superﬁcial tumors, and ethanol injec-
tion therapy can only achieve a complete necrosis of
approximately 70%, even for tumors <3 cm. RFA is
a better modality for treatment of the contralateral
lesions and could even be used for deep-seated le-
sions. The strategy of RFA combined with resection
is particularly useful for patients with a large tumor
in one lobe and one or two smaller tumor nodules in
the contralateral lobe, for which neither resection or
RFA alone is adequate for treatment.
Although the strategy of combined RFA and
resection may reduce the surgical risk compared with
an extended hepatectomy aimed to encompass multi-
ple tumors, it is still a high-risk procedure in patients
who have limited liver function reserve. Choi et al.
reported no operative mortality and an 8% major
complication rate, which are indeed very favorable
results.However,itshouldbenotedthattheirselection
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3299retentionat15minutesisquiterestrictive.Inmycenter,
theselectioncriterionformajorliverresectionhasbeen
extended to cirrhotic patients with indocyanine green
retention at 15 minutes up to 20%.
8 It is possible that
some of the patients with multifocal tumors treated
withRFAcombinedwithresectioninthestudyofChoi
et al. could have been treated by extended hepatic
resection. None of the patients in the study had re-
ceivedrightportalveinembolizationbeforesurgery.In
patients with mild cirrhosis, right portal vein emboli-
zation is effective in inducing hypertrophy of the left
lateral segment and may allow safe resection of mul-
tifocal tumors conﬁned to right lobe and segment 4.
9
The role of combined RFA and resection is more
important in patients with marked cirrhosis and truly
borderlineliverfunction.ThesafetyofRFAcombined
with major resection in such patients remains to be
evaluated.
The 5-year survival rate of 55% after combined
resection and RFA in the study of Choi et al. is
encouraging. Of a total of 66 tumors ablated, there
was only one incomplete ablation and another two
with local tumor progression after a median follow-
up of 22 months in the whole group. However, the 5-
year cancer-free survival was 0%, indicating that tu-
mor recurrence at other parts of the liver or extra-
hepatic sites is a major problem. The presence of
multifocal tumors implies either a high propensity for
multicentric carcinogenesis or intrahepatic metastasis
from a dominant tumor. A high recurrence rate in
patients with multifocal tumors after combined RFA
and resection is expected. Thus far, there is no well-
established adjuvant therapy that could reduce tumor
recurrence after resection or RFA. To further im-
prove the long-term outcome, it is imperative that
more research eﬀort is devoted to the study of novel
adjuvant therapies for HCC.
Although the study of Choi et al. demonstrated
favorable results of RFA combined with resection for
multifocal HCCs, it remain unclear to what extent
this could increase the chance of curative treatment
for tumors otherwise not considered curable. The
eﬀect of RFA in this aspect could only be clariﬁed by
comparing the management of multifocal HCCs be-
fore and after availability of RFA. Further studies
should also compare the outcome of RFA combined
with resection with that of patients with resection
alone to see whether the survival results are truly
comparable. Nonetheless, RFA combined with
resection should be considered the treatment of
choice for multifocal HCCs that are otherwise not
amenable to resection or liver transplantation.
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